Experienced in Magnesium Deficiency

Dr. Amina Z. Haggag

Family Medicine
18406 Roscoe Blvd, 
Northridge, CA 
Experienced in Magnesium Deficiency
18406 Roscoe Blvd, 
Northridge, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amina Haggag is a primary care provider, practicing in Family Medicine in Northridge, California. Dr. Haggag is rated as an Experienced provider by MediFind in the treatment of Magnesium Deficiency. Her top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Magnesium Deficiency.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Magnesium Deficiency.

Specialties
Family Medicine
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

18406 Roscoe Blvd, Northridge, CA 91325

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drugs: LY3502970, Dulaglutide
Study Phase: Phase 2
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Enrollment Status: Terminated
Publish Date: August 26, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

5 Total Publications

Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Journal: Diabetes, obesity & metabolism
Published: September 20, 2024
Similar Doctors
Distinguished in Magnesium Deficiency
Dr. David R. Miller
Family Medicine
Distinguished in Magnesium Deficiency
Dr. David R. Miller
Family Medicine
28240 Agoura Rd, Suite 102, 
Agoura Hills, CA 
 (13.1 miles away)
818-706-9690
Languages Spoken:
English
See accepted insurances

David Miller is a primary care provider, practicing in Family Medicine in Agoura Hills, California. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Magnesium Deficiency, Gitelman Syndrome, Cystoisosporiasis, and High Cholesterol.

Advanced in Magnesium Deficiency
Dr. Maria C. De Leon
Family Medicine | General Practice | Geriatrics
Advanced in Magnesium Deficiency
Dr. Maria C. De Leon
Family Medicine | General Practice | Geriatrics

Bella Medical Group Inc

2933 Whittier Blvd, 
Los Angeles, CA 
 (22.8 miles away)
323-263-2669
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maria De Leon is a primary care provider, practicing in Family Medicine and Internal Medicine in Los Angeles, California. Dr. De Leon is rated as a Distinguished provider by MediFind in the treatment of Magnesium Deficiency. Her top areas of expertise are Osteoarthritis, Maturity Onset Diabetes of the Young, High Cholesterol, and Type 2 Diabetes (T2D).

Advanced in Magnesium Deficiency
Dr. Daisy I. Bautista
Family Medicine | Pediatrics | General Practice
Advanced in Magnesium Deficiency
Dr. Daisy I. Bautista
Family Medicine | Pediatrics | General Practice

Mobile Medical Group Inc.

130 N Brand Blvd, Suite 208, 
Glendale, CA 
 (16.8 miles away)
818-945-6003
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daisy Bautista is a primary care provider, practicing in Family Medicine and Pediatrics in Glendale, California. Dr. Bautista is rated as an Advanced provider by MediFind in the treatment of Magnesium Deficiency. Her top areas of expertise are Osteoarthritis, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Hypertension.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haggag's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile